Why Nutritional Care Matters for People Living with Mitochondrial Disease
7 Sep, 2026
Good nutrition is an important part of managing many rare neuromuscular conditions, including mitochondrial diseases. A new educational flyer, funded […]...
Germany Takes a Major Step Toward Access to TK2d Therapy
2 Sep, 2026
A significant milestone has been reached for families affected by TK2d: Germany has now formally recognised Kygevvi®, the first disease‑specific […]...
Strengthening Connections: IMP’s Ambassador Meetings
2 Sep, 2026
IMP has begun hosting regular Ambassador Meetings, creating a welcoming space for representatives from our member organisations to connect, share updates, […]...
LHON Webinar: 19 September – registration open
2 Sep, 2026
The LHON Awareness Day Webinar is approaching quickly, taking place on 19 September (13:00–15:00 CEST). This year’s theme — Best practices in LHON: stories […]...
Updated TK2d videos now available
2 Sep, 2026
Three new TK2d Awareness Day videos are being released in the lead‑up to 8 September, each sharing a deeply personal […]...
ERN‑RND Scientific Symposium: Registries for Rare Neurological Diseases
2 Sep, 2026
On 10 October 2026, the European Reference Network for Rare Neurological Diseases (ERN‑RND) will host a dedicated scientific symposium focused on […]...
Patient‑Focused Drug Development Meeting on POLG
2 Sep, 2026
A Landmark Moment for the POLG Community – 17 November 2026 On 17 November, MitoAction will host its first Patient‑Focused Drug Development […]...
Pretzel Therapeutics Answers Key Questions from the POLG Community
2 Sep, 2026
Following the POLG Foundation Summit, Pretzel Therapeutics has shared updated answers to community questions about PX578, their first‑in‑class investigational therapy for […]...
A Major Step Forward for the Global POLG Community
2 Sep, 2026
FDA clears PX578 to enter Phase 2 clinical testing At IMP, few moments bring more hope than seeing innovative science […]...
New Natural History Study Sheds Light on MNGIE
2 Sep, 2026
A new retrospective natural history study from the MitoCAMB team at the University of Cambridge offers important insights into mitochondrial neurogastrointestinal […]...
Germany Takes a Major Step Toward Access to TK2d Therapy
2 Sep, 2026
A significant milestone has been reached for families affected by TK2d: Germany has now formally recognised Kygevvi®, the first disease‑specific […]...
New Study Strengthens Patient‑Centred Endpoint Selection for KHENERFIN Phase 3 Trial
2 Sep, 2026
Khondrion has announced the publication of an important qualitative study in Orphanet Journal of Rare Diseases examining the lived experience […]...
The Effects of Hydrogen Sulfide, VOCs and Bioaerosols on People with Mitochondrial Disease
2 Sep, 2026
Written by Paula Morandi, Chair of IMP Why emissions from olive‑pomace fermentation pose a serious health risk The open‑air fermentation […]...
A note from the Chair: One Voice, 25 Nations — The Power of Our Global Umbrella
28 Aug, 2026
Paula Morandi, Chair of IMP When you hear the acronym IMP, what comes to mind? To many, International Mito Patients […]...
IMP Annual Meeting 2026 – Celebrating 15 years
10 Jul, 2026
The International Mito Patients (IMP) Annual Meeting 2026 brought together advocates, clinicians, researchers and partners from around the world to […]...
Registration is now open for the TK2d International Webinar 2026 .
10 Jul, 2026
TK2d across countries: diagnosis, multidisciplinary care and therapeutic pathways Registration is now open for the international webinar “TK2d Across Countries: Diagnosis, […]...
A word from our new member ASANOL
7 Jul, 2026
On 29 May, we had the opportunity to participate, for the first time as ASANOL, in the International Mito Patients meeting […]...
World Mitochondrial Disease Week 2026: Putting Mito on the Map
7 Jul, 2026
We’re delighted to announce the launch of this year’s World Mitochondrial Disease Week theme: “Putting Mito on the Map.” Members asked […]...
New Patient Journey for Primary Mitochondrial Myopathies Launched
7 Jul, 2026
IMP has worked with ERN EURO‑NMD and several leading patient organisations, including Mitocon, the Bulgarian Association for Neuromuscular Diseases, and […]...
New TK2d Early Symptom Reflection Tool Supports Better Clinical Conversations
30 Jun, 2026
UMDF, in collaboration with UCB, has launched a new resource designed specifically for people living with TK2d and those who […]...
